Genprex

Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company’s lead product candidate is REQORSA immunogene therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Genprex Inc. (NASDAQ:GNPX) has announced that its research collaborators at the University of Pittsburgh will present preclinical data highlighting the therapeutic potential of Genprex's gene therapy for Type 1 diabetes at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) being held February 22-25, 2023, in Berlin, Germany and online. "ATTD 2023 presents an ideal opportunity for the results of this important study to be presented to the diabetes community.

Genprex says research collaborators to present preclinical data highlighting potential of its gene therapy for Type 1 diabetes at Berlin conference

Exciting Data from University of Pittsburgh Researchers in Non Human Primates that Underpins Genprex's Gene Therapy Program in Diabetes to be Showcased AUSTIN, Texas , Jan. 4, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators at the University of Pittsburgh will present preclinical data highlighting the therapeutic potential of Genprex's gene therapy for Type 1 diabetes at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) being held February 22-25 in Berlin, Germany and online. "ATTD 2023 presents an ideal opportunity for the results of this important study to be presented to the diabetes community.

Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabetes

Genprex, Inc. (NASDAQ:GNPX) revealed that it has struck an agreement with the University of Pittsburgh for a worldwide, exclusive license to some patent applications and a worldwide, non-exclusive license to use certain related know-how, all related to modulating autoimmunity in Type 1 diabetes by using gene therapy. The Austin, Texas-based clinical-stage gene therapy company focused on developing novel therapies for patients with cancer and diabetes, noted that the preclinical technology transforms macrophages enabling them to reduce autoimmune activity in Type 1 diabetes and could be complementary to the company's existing diabetes technology.

Genprex boosts its diabetes gene therapy program with the license of additional technology from the University of Pittsburgh

Technology for modulating autoimmunity expands intellectual property portfolio AUSTIN, Texas , Dec. 15, 2022 /PRNewswire/ --  Genprex, Inc.  ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement (the Agreement) with the University of Pittsburgh, granting Genprex a worldwide, exclusive license to certain patent applications and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to modulating autoimmunity in Type 1 diabetes by using gene therapy. The preclinical technology transforms macrophages enabling them to reduce autoimmune activity in Type 1 diabetes and could be complementary to the Company's existing diabetes technology.

Genprex Strengthens Diabetes Gene Therapy Program with License of Additional Technology from University of Pittsburgh

Genprex, Inc. (NASDAQ:GNPX) has announced that the Safety Review Committee (SRC) has approved continuation to the third and final cohort in the dose escalation Phase 1 portion of the Acclaim-1 Phase 1/2 clinical trial of REQORSA in combination with Tagrisso (osimertinib) to treat late-stage non-small cell lung cancer (NSCLC).  The SRC is comprised of three physicians who are principal investigators in the trial.

Genprex gets green light for continuation of dose escalation Phase 1 of Acclaim-1 Phase 1/2 clinical trial of REQORSA

Recommendation to Advance to Increased Dose in Third and Final Cohort of Phase 1 Portion of Trial Indicates Favorable Safety Profile of Novel Gene Therapy in Solid Tumor Cancer AUSTIN, Texas , Dec. 14, 2022 /PRNewswire/ -- Genprex, Inc.  ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Safety Review Committee (SRC) has approved continuation to the third and final cohort in the dose escalation Phase 1 portion of the Acclaim-1 Phase 1/2 clinical trial of REQORSA® in combination with Tagrisso® (osimertinib) to treat late-stage non-small cell lung cancer (NSCLC). In 2020, the combination of REQORSA and osimertinib received U.S. Food and Drug Administration's (FDA) Fast Track Designation for treatment of the Acclaim-1 patient population.

Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer

Corporate Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Dec. 2, 2022 /PRNewswire/ -- Genprex, Inc.  ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its Executive Vice President, General Counsel and Chief Strategy Officer, Catherine Vaczy, will be providing an overview of the Company's gene therapies for cancer and diabetes at the following investor conference in December 2022. Event: RHK 2022 Disruptive Growth Conference Conference Dates: Dec. 5-6, 2022 Presentation Date: Tuesday, Dec. 6, 2022 Presentation Time: 2:40 p.m.

Genprex to Present at Upcoming December Investor Conference

Corporate and Clinical Presentations to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Oct. 7, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming investor and industry conferences to be held in October 2022. Event: Dawson James Securities Annual Small Cap Growth Conference Conference Date: October 12, 2022 Presentation Date: October 12, 2022 Presentation Time: 9:00 a.m.

Genprex to Present at Upcoming October Investor and Industry Conferences

Analysts at Noble Capital have reiterated an 'Outperform' rating and $5 price target on Genprex Inc which recently announced that the first cohort from its Phase 1/2 Acclaim-1 trial in non-small cell lung cancer (NSCLC) has shown sufficient safety to allow treatment of a second cohort at a higher dose. The approval came from the Safety Review Committee (SRC) after it analyzed patient data in the first cohort.

Analysts at Noble Capital reiterate 'Outperform' rating and $5 price target on Genprex

Genprex, Inc. (NASDAQ:GNPX) said the company has been issued a patent that covers using REQORSA Immunogene Therapy in conjunction with immune checkpoint inhibitors for lung cancer. Thomas Gallagher, senior vice president of Intellectual Property and Licensing at Genprex, said the United States Patent and Trademark Office has granted US Patent No.

Genprex announces US patent for REQORSA Immunogene Therapy in combination with immune checkpoint inhibitors to treat cancers

Provides Protection for Therapeutic Combination in Acclaim-2 Phase 1/2 Clinical Trial AUSTIN, Texas , Aug. 16, 2022 /PRNewswire/ --  Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the United States Patent and Trademark Office (USPTO) has granted Genprex U.S. Patent No: 11,278,592 B2. The patent covers methods of using REQORSATM Immunogene Therapy in conjunction with immune checkpoint inhibitors, through 2038.

Genprex Announces U.S. Patent for REQORSA™ Immunogene Therapy in Combination with Immune Checkpoint Inhibitors to Treat Cancers

Genprex, Inc. (NASDAQ:GNPX) announced that the Safety Review Committee (SRC) has approved a continuation of the Acclaim-1 Phase 1/2 clinical trial of the company's lead drug candidate REQORSA in combination with Tagrisso (osimertinib) to treat late-stage non-small cell lung cancer (NSCLC). The approval follows a review of the first cohort of patients in Phase 1 by the SRC, which comprised of three physicians who are principal investigators in the trial, the clinical-stage gene therapy company said.

Genprex secures higher dose approval for REQORSA in combination with Tagrisso Phase 1 clinical trial

Recommends Advancing Acclaim-1 to Increased Dose in Second Cohort of Phase 1 Portion of Trial AUSTIN, Texas , Aug. 15, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Safety Review Committee (SRC) has approved continuation of the Acclaim-1 Phase 1/2 clinical trial of REQORSA™ in combination with Tagrisso® (osimertinib) to treat late-stage non-small cell lung cancer (NSCLC) following a review of the first cohort of patients in the Phase 1 portion of the trial. In 2020, Genprex received U.S. Food and Drug Administration's (FDA) Fast Track Designation for treatment of the Acclaim-1 patient population.

Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer

Company Manufacturing Leads Selected as Thought Leaders to Discuss Advances in Lipid Nanoparticle Delivery Systems AUSTIN, Texas , July 13, 2022 /PRNewswire/ --  Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that Company manufacturing leadership will present sessions on cutting edge topics in lipid-based nanoparticle delivery systems at the upcoming Next Generation Lipid-Based Nanoparticles Delivery Summit taking place from July 19-21, 2022 in Boston.     Presentation Session: Navigating New Payloads & Advanced Delivery Presentation Title: Challenges in Translating Innovative Gene Therapy Drug Targets for Accelerated Development & IND/BLA Submissions Presentation Date: July 21, 2022 Presentation Time: 2:15 p.m.

Genprex to Participate in Next Generation Lipid-Based Nanoparticles Delivery Summit

Corporate Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , June 2, 2022 /PRNewswire/ --  Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming investor and industry conferences to be held in June 2022. Event: LD Micro Invitational  Conference Dates: June 7-9, 2022  Presentation Date: June 8, 2022  Presentation Time: 4:00 p.m.

Genprex to Present at Upcoming June Investor Conferences

Corporate Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 19, 2022 /PRNewswire/ --  Genprex, Inc.  ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its President and Chief Executive Officer, Rodney Varner, will be providing a virtual overview of the Company's gene therapies for cancer and diabetes to investors at the following conference in May 2022. Event: H.C.

Genprex to Present at Upcoming Investor Conference in May 2022

Live panel discussion will explore considerations with respect to positioning of cell-based and other emerging immunotherapy platforms in solid tumors AUSTIN, Texas , May 9, 2022 /PRNewswire/ -- Genprex, Inc.  ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its Chief Medical Officer, Mark Berger, M.D., will be featured as an expert panelist at the 33rd Annual Cancer Progress Conference, taking place virtually May 10-12, 2022.

Genprex's Chief Medical Officer to Be Featured as an Expert Panelist at the 33rd Annual Cancer Progress Conference

Genprex Inc CEO Rodney Varner said the clinical stage gene therapy company has achieved “many key milestones” already this year in a letter to shareholders.  So far, "We announced our second Fast Track Designation for REQORSA Immunogene Therapy, we commenced patient treatment in our Phase 1/2 Acclaim-1 clinical trial for non-small cell lung cancer (NSCLC), we opened our Phase 1/2 Acclaim-2 clinical trial for NSCLC and commenced patient treatment in that trial,.

Genprex CEO shares key progress for non-small cell lung cancer treatment REQORSA in shareholder letter

Company achieves major milestones in clinical development programs in 2022 Patient treatment in Acclaim-2 clinical trial commences AUSTIN, Texas , May 5, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has issued a shareholder letter and corporate update outlining the Company's recent progress in its clinical development programs and key milestones and achievements for 2022 and beyond. "We have had a strong start to this year, achieving many key milestones for our Company," said Rodney Varner, President and Chief Executive Officer of Genprex.

Genprex Issues Shareholder Letter and Provides 2022 Corporate Update

Presentations to highlight the Company's gene therapies for cancer and diabetes AUSTIN, Texas , April 18, 2022 /PRNewswire/ -- Genprex, Inc.  ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its executive leaders will be providing an overview of the Company's gene therapies for cancer and diabetes to investors and industry professionals at the following investor and industry conferences in April 2022. Event: NobleCon 18 Conference Dates: April 19-21, 2022 Presentation Date: Wednesday, April 20 Presentation Time: 11:30 a.m.

Genprex to Participate in Upcoming Investor and Industry Conferences in April 2022

Genprex Inc said it has opened patient enrollment for its Acclaim-2 clinical trial evaluating the company's lead drug candidate, REQORSA Immunogene Therapy. Acclaim-2 is an open-label, multi-center Phase 1/2 clinical trial evaluating REQORSA Immunogene Therapy in combination with Keytruda (pembrolizumab) in patients with late-stage non-small cell lung cancer (NSCLC) whose disease progressed after treatment with Keytruda.

Genprex announces opening of patient enrollment for its Acclaim-2 clinical trial

AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces it has opened its Acclaim-2 clinical trial for patient enrollment.

Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces participation in March conferences.

Genprex to Participate in Upcoming Investor Conference in March

AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces the dosing of its first patient in its Acclaim-1 clinical trial in non-small cell lung cancer

Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces participation in February conferences.

News for Genprex Stock (GNPX)